Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. Longboard recently reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants ages 12 to 65 years old with Developmental and Epileptic Encephalopathies (DEEs), including Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions.
Longboard Pharmaceuticals的外部链接
4275 Executive Square
Suite 950
US，CA，La Jolla，92037
We are thrilled to be the first partner in the Allies in Research Program with the Pediatric Epilepsy Research Consortium! We look forward to collaborating with this amazing network to support the pediatric epilepsy community.
PERC is pleased to announce Longboard Pharmaceuticals as our first participant in the Allies in Research Program supporting the research mission of PERC! Learn more about the AIR program here: https://lnkd.in/gCSNPNKw
Another great accomplishment for our team! We are so pleased to announce that we initiated our Phase 3 DEEp Program - starting with DEEp SEA in #DravetSyndrome. Please click here for additional detail. https://bit.ly/4eDV4uj
Today, we announced Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome - another terrific regulatory milestone! Additional details available here https://bit.ly/3XzAKna
Thank you to everyone who attended our R&D Day in NYC yesterday! The replay is available here. https://bit.ly/3OEgIEd
Thank you to Patrick R. Trucchio & H.C. Wainwright & Co., LLC for hosting us at the 26th Annual Global Investor Conference. A webcast of our fireside chat with our CFO, Brandi Roberts is available here. https://bit.ly/4dUchzZ #HCWainwrightGlobal
Today, we announced positive interim results from our ongoing open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin in participants with DEEs. Our CMO, Randall Kaye, presented these data at the International League Against Epilepsy 15th European Epilepsy Congress. For more detail on the OLE results visit the following link https://bit.ly/4ed1KPP #EEC2024 #EEC
We are #hiring in the US, EU, AUS and more! Please see our open positions here: https://lnkd.in/gBVEBrXx #clinicaloperations #clincialpharmacology #medicalaffairs #biotechjobs
We are pleased to be chosen as one of the Best Places to Work in San Diego - Thank you to the San Diego Business Journal for this honor! At Longboard, we foster a company culture that is both collaborative and inclusive, and we believe that is essential for innovation and success. We are driven by our common mission to develop novel, transformative medicines for people living with devastating neurological conditions.
We’re grateful to the Angelman Syndrome Foundation and Dup15q Alliance for the opportunity to share our PACIFIC Study data at their joint research symposium last week. Witnessing their resilience and commitment to advance treatments for their community is truly inspiring. Thank you for including us in this terrific event!?